The Food and Drug Administration has approved the first generic opioid overdose nasal spray. The drug is a generic version of Narcan, the branded naloxone nasal spray made by Emergent BioSolutions. The approval of this generic, made by Teva, is part of the FDA’s effort to make tools for stopping or preventing overdoses more accessible and widely used. (Time)

Several executives at cannabis company MedMen have resigned. The company’s COO, general counsel and corporate communications SVP have departed. Another former executive, MedMen’s former CFO, left recently and filed a lawsuit for wrongful dismissal. (CNBC)

A Pfizer-Eli Lilly painkiller has missed goals in a late-stage study. A trial testing the lower dose of a non-opioid painkiller failed in a study in patients with moderate to severe osteoarthritis of the hip or knee. Another trial of a higher dose of the same drug met two of three goals. (Reuters)

This year’s flu season is the longest in a decade. A second wave of the virus that hit in mid-February turned the flu season from a short, mild year to one of the longest. The season has been going for 21 weeks. (Associated Press)

Carolyn Magill, one of MM&M’s 2019 Healthcare Transformers, says pharma needs to embrace more data. Magill, CEO of health tech company Aetion, wrote that the industry is undergoing a massive shift as real-world data and advanced tools to analyze it become more common. (MedCity News)